» Articles » PMID: 24786898

Altered Subcellular Localization of IL-33 Leads to Non-resolving Lethal Inflammation

Overview
Journal J Autoimmun
Date 2014 May 3
PMID 24786898
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Non-resolving inflammation is a major contributor to chronic disease pathogenesis, including that of cancer, chronic obstructive pulmonary disease, asthma, arthritis, inflammatory bowel disease, multiple sclerosis and obesity. Some cytokines, such as IL-1α and IL-33, may act as endogenous alarmins that contribute to non-resolving inflammation. These cytokines are constitutively expressed in the nucleus and are thought to promote inflammation only upon release during tissue damage or cell necrosis. However, the importance of their nuclear localization in immune homeostasis is not fully understood. We describe herein a novel mouse model in which the nuclear localization signal of IL-33 is abolished and demonstrate for the first time that, alone, altered subcellular localization of IL-33 dramatically affects immune homeostasis. Heterozygous IL33(tm1/+) mice display elevated serum IL-33 levels, indicating that IL-33 is constitutively released when not actively targeted to the nucleus. IL33(tm1/+) mice succumb to lethal inflammation characterized by eosinophil-dominated immune cell infiltration of multiple organs. The profound inflammatory phenotype is dependent on mediators downstream of ST2 as ST2-null mice are protected in spite of high serum IL-33 levels. Importantly, IL-33 transcript levels in this knock-in mouse model remain under endogenous control. We adopt the term "nuclear alarmin" to describe a danger signal that is primarily regulated by nuclear compartmentalization in this fashion.

Citing Articles

Interleukin-33: A Double-Edged Sword in Sepsis.

Liu S, Yue Y, Wu Q, Zhang L Transl Perioper Pain Med. 2025; 11(2):612-619.

PMID: 39991638 PMC: 11845250. DOI: 10.31480/2330-4871/188.


Interleukin-33 promotes intrauterine adhesion formation in mice through the mitogen-activated protein kinase signaling pathway.

Liu D, Yuan L, Xu F, Ma Y, Zhang H, Jin Y Commun Biol. 2024; 7(1):1022.

PMID: 39164588 PMC: 11336135. DOI: 10.1038/s42003-024-06709-1.


Cancer stem cells release interleukin-33 within large oncosomes to promote immunosuppressive differentiation of macrophage precursors.

Erickson H, Taniguchi S, Raman A, Leitenberger J, V Malhotra S, Oshimori N Immunity. 2024; 57(8):1908-1922.e6.

PMID: 39079535 PMC: 11324407. DOI: 10.1016/j.immuni.2024.07.004.


Anti-Melanogenic and Anti-Inflammatory Effects of 2'-Hydroxy-4',6'-dimethoxychalcone in B16F10 and RAW264.7 Cells.

Bae S, Lee J, Hyun C Curr Issues Mol Biol. 2024; 46(6):6018-6040.

PMID: 38921030 PMC: 11202956. DOI: 10.3390/cimb46060359.


The role of interleukin-33 in organ fibrosis.

Di Carmine S, Scott M, McLean M, McSorley H Discov Immunol. 2024; 1(1):kyac006.

PMID: 38566909 PMC: 10917208. DOI: 10.1093/discim/kyac006.